Basilea Pharmaceutica AG Sustainability Reports

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company that develops and commercializes innovative drugs targeting severe bacterial and fungal infections. The company has successfully brought to market treatments including the antifungal Cresemba and the antibacterial Zevtera.

Sector: Manufacturing

Country: Switzerland

Exchange: SIX Swiss Exchange

LEI: 391200TTZP8EIPSJ5J20

FIGI: BBG001SCQ314

3 reports from 2014 to 2025

• Basilea Pharmaceutica AG 2025 Short Annual Report
• Basilea Pharmaceutica AG 2025 Our ESG Commitment
• Basilea Pharmaceutica AG 2014 Annual Report